Decoding neurotoxicity: A multi-disease single-cell atlas of cerebrospinal fluid reveals conserved and context-specific pathogenic hallmarks

X Xia Li W Wanying Zhang J Jiehan Liang (1The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hang zhou, China) S Shaogang Li Y Yinnan Tong (1The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hang zhou, China) T Tingfeng Shen (1The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hang zhou, China) H Haikun Lin (1The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hang zhou, China) Y Yongxian Hu (1Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China) F Fang Ye H He Huang

Abstract

Abstract Introduction:​ Disease-induced neurotoxicity represents a significant clinical challenge across various neurological conditions, causing long-term or even fatal damage to the central nervous system (CNS). Cerebrospinal fluid (CSF), a critical component of CNS homeostasis, functions by mediating immune surveillance and regulating neuroimmune responses. However, the specific characteristics of disease-associated neurotoxicity and the cellular heterogeneity ​​within​​ CSF remain largely uncharacterized. Methods and Results: We established the multi-disease single-cell transcriptome atlas of CSF immunity, profiling 154,111 cells from 105 samples across 8 neurotoxic conditions, including aging, Alzheimer's disease and mild cognitive impairment (AD/MCI), CAR-T associated neurotoxicity (neuro-CAR-T), COVID with neurological sequelae (neuro-COVID19), postherpetic neuralgia (PHN), viral encephalitis (VE), ​​multiple sclerosis (MS) and ​​idiopathic intracranial hypertension (IIH). Leveraging disease-specific cellular heterogeneity, we identified three principal neurotoxicity drivers: i) Lipid metabolism-correlated inflammation: Characterized by the dominance of PPAR pathway enriching SPP1+ macrophages, and lipid-metabolizing COX4I1+ macrophages as key drivers of neuroinflammation (e.g., neuro-CAR-T and VE). (ii) Virally-triggered neuroinflammation:​​ Featured by ​​interferon signaling-mediated antiviral responses​​ and characterized by the enrichment of ​​anti-virus NK cells and ​​CD14+CD16+ intermediate monocytes​​, particularly prominent in ​​VE and neuro-COVID-19​​. iii) B-lineage dichotomy: Defined by plasma cell expansion in inflammatory contexts (e.g., MS, VE) contrasting with B cell prevalence in senescent states (e.g., aging and AD/MCI). Furthermore, integrative analysis of transcriptomic profiles and disease-related neurotoxic factors delineated four distinct molecular patterns of neurotoxic pathogenesis: (i) an ​​interferon-dominant, virally-triggered​​ pattern, (ii) a ​lipid-metabolism-dysregulated, CAR-T-induced​ pattern, (iii) a ​​translation-perturbed, ribosome-related​​ pattern, and (iv) an ​​aging-associated​​ pattern with prominent mitochondrial impairment.​​ Notably, despite transcriptional differences across patterns, comparative analyses deciphered the critical convergent role of myeloid compartment in driving neuroinflammation. Significance: Our study presented ​​one of the largest human CSF single-cell RNA immunology atlases to date​​, comprising 154,111 cells across 8 neurotoxic conditions. We delineated conserved and disease-specific neurotoxic mechanisms, identifying myeloid cells as pivotal regulators of neuroinflammation. The discovered molecular patterns offer diagnostic biomarkers for early detection, reveal both universal and specific therapeutic targets, and shed light on potential precision medicine for neurotoxic complications.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 1227-1227
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (10)

X

Xia Li

W

Wanying Zhang

J

Jiehan Liang

1The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hang zhou, China

S

Shaogang Li

Y

Yinnan Tong

1The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hang zhou, China

T

Tingfeng Shen

1The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hang zhou, China

H

Haikun Lin

1The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hang zhou, China

Y

Yongxian Hu

1Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

F

Fang Ye

H

He Huang